Sam Horng, MD, PhD
- ASSISTANT PROFESSOR | Neurology, Multiple Sclerosis
Research Topics:Blood-Brain Barrier, Brain Imaging, Chemokines, Cytokines, Demyelination, Immunology, Multiple Sclerosis, Neuro-degeneration/protection, Neurobiology, Neurology, Neuroscience
Sam Horng, MD, PhD, received his B.A. in biology, summa cum laude, from Columbia University, then trained as a pre-doctoral fellow in clinical bioethics at the National Institutes of Health. He completed his MD and PhD degree at Harvard Medical School and the Massachusetts Institute of Technology, where his graduate research investigated how early patterning events specify different sensory areas of the thalamus and cortex.
Dr. Horng completed his medical internship at Yale New Haven Hospital and his neurology residency at Mount Sinai Hospital, where he served as chief resident and was awarded an R25 Research in Residency grant from the National Institutes of Health and a Leon Levy Neuroscience Fellowship from 2015 to 2017 to study mechanisms of blood-brain barrier breakdown in inflammatory brain disease.
Dr. Horng investigates the role of specialized blood-brain barrier cells called astrocytes in controlling immune cell entry into the brain during autoimmune attack. He recently published work featured on the cover of The Journal of Clinical Investigation, demonstrating for the first time, that astrocytes act as an inducible barrier to immune cell entry in the early stages of autoimmune attack.
His laboratory is now focused on identifying specific contact-mediated interactions between astrocytes and immune cells, hypothesizing that astrocytes activate immune cells and control subsequent steps in the process of autoimmune attack. He aims to translate this work towards treatment strategies for multiple sclerosis and other CNS autoimmune diseases.
Dr. Horng offers telemedicine appointments when appropriate. Please call his office to schedule a video visit.
Dr. Horng is registered to provide telehealth services in Florida.
- Demyelinating Disease
- Gadolinium Enhancing Lesions
- Lumbar Puncture
- Multiple Sclerosis
- Neuromyelitis Optica
Multi-Disciplinary Training AreaNeuroscience [NEU]
MD,PHD, Harvard Medical School
BA, Columbia University
PhD, Massachusetts Institute of Technology
Internship, Internal Medicine, Yale-New Haven Hospital
Residency, Neurology, Mount Sinai School of Medicine
Fellowship, Multiple Sclerosis, Mount Sinai School of Medicine
K08 Mentored Clinical Scientist Research Career Development Award
Research Fellowship in Neuroscience
Arnold P. Gold Foundation’s Humanism and Excellence in Teaching Award
F30 Predoctoral NRSA Fellowship
Clinical disability in multiple sclerosis (MS) is driven by immune cell infiltration into the CNS parenchy-ma. Understanding the mechanisms by which CNS barrier cells regulate immune cell activation and en-try during this infiltrative process may identify novel therapeutic strategies for MS and other CNS auto-immune diseases.
During CNS inflammation, immune cells traffic from the blood through a two-barrier structure termed the neurovascular unit. While many have focused on entry through the first barrier, a specialized en-dothelial wall known as the blood-brain barrier, less is known about how immune cells interact with the second barrier, a layer of endfoot processes extending from specialized cells called astrocytes, a barrier referred to as the glia limitans. In MS lesions, immune cells circulate within the space between the first and second barriers, a compartment termed the perivascular space. Within this space, immune cells interact with the astrocyte endfeet and potentially receive signals that prime them for autoimmune attack.
The Horng Laboratory is interested in identifying and characterizing the signaling pathways between astrocytes and immune cells within the perivascular spaces. We are testing the hypothesis that this cross-talk regulates immune cell function prior to CNS entry and induces functional differentiation in both cell types which contributes to both the acute phase of CNS inflammation and more chronic processes of neurodegeneration.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Horng did not report having any of the following types of financial relationships with industry during 2022 and/or 2023: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.